Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Integration of single-cell and bulk RNA sequencing to identify a distinct tumor stem cells and construct a novel prognostic signature for evaluating prognosis and immunotherapy in LUAD

Fig. 6

Comparison of anti-tumor drug sensitivity between high-risk and low-risk groups. A Bortezomib, Pazopanib, AKT inhibitor VIII, AZD6482, CGP.082996, and CEP-701 demonstrated enhanced drug sensitivity in the high-risk group. B CCT007093, GDC.0449, and Lapatinib exhibited superior drug sensitivity in the low-risk group. Statistics based on Wilcoxon test

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us